Seer Board Rejects $2.40 Per Share Bid from Radoff-JEC Group
Event summary
- Seer's Board unanimously rejected a revised unsolicited proposal from the Radoff-JEC Group on May 21, 2026.
- The offer was $2.40 per share in cash plus a contingent value right, deemed undervalued by Seer's Board.
- The Board cited the proposal's equity value as significantly below Seer's current cash and investments.
- This rejection follows the Board's prior rejection of a similar proposal on April 27, 2026.
The big picture
Seer's rejection of the Radoff-JEC Group's proposal underscores the Board's confidence in the company's long-term growth prospects despite the current undervaluation. This move aligns with broader trends in biotech, where companies often resist short-term financial offers in favor of sustaining innovation and market positioning. The Proteograph Product Suite's unique capabilities in proteomics further solidify Seer's strategic importance in the industry.
What we're watching
- Hostile Takeover Risk
- Whether the Radoff-JEC Group will escalate its bid or seek alternative acquisition strategies.
- Shareholder Sentiment
- How Seer's stockholders will react to the Board's rejection and the perceived undervaluation.
- Strategic Alternatives
- The pace at which Seer explores other strategic options to enhance shareholder value.
Related topics